```html

Quinine Toxicity (Cinchonism)

Overview

Quinine toxicity, also called cinchonism, is a dose‑dependent adverse reaction that occurs when a person ingests too much quinine or related alkaloids. Quinine is a naturally occurring compound extracted from the bark of the cinchona tree and has been used for centuries to treat malaria and, more recently, for nocturnal leg cramps, bitter‑taste sweeteners, and certain cardiac arrhythmias.

• **Prevalence** – In the United States, quinine‑containing over‑the‑counter (OTC) products are limited, but an estimated 2–4 % of adults who take quinine for leg cramps report mild symptoms of cinchonism<sup>1</sup>. Severe toxicity is rare, with < 0.5 % of users requiring medical attention.
• **Who it affects** – Anyone who consumes quinine—whether prescribed, taken as a supplement, or ingested unintentionally (e.g., contaminated beverages)—can develop cinchonism. Older adults, patients with renal or hepatic impairment, and those on interacting medications are at higher risk.

Symptoms

Symptoms typically appear within 30 minutes to a few hours after ingestion and are dose‑related. They can be grouped into mild, moderate, and severe categories.

Mild Cinchonism (≤ 400 mg/day)

• Tinnitus – Ringing or buzzing in the ears.
• Headache – Often described as a dull, throbbing pain.
• Disturbed taste – Metallic or bitter taste (dysgeusia).
• Nausea & vomiting – Usually mild and self‑limiting.
• Visual disturbances – Blurred vision or photophobia.

Moderate Cinchonism (400‑800 mg/day)

• All mild symptoms, plus:
• Vertigo or dizziness – Feeling off‑balance.
• Hearing loss – Temporary reduction in hearing acuity.
• Myalgias – Generalized muscle aches.
• Diarrhea – Occurs in up to 10 % of moderate cases.

Severe Toxicity (> 800 mg/day or rapid IV infusion)

• Progression to quinine‑induced hemolytic anemia (especially in patients with G6PD deficiency).
• Thrombocytopenia – Low platelet counts leading to easy bruising.
• Cardiac arrhythmias – Including QT prolongation and torsades de pointes.
• Renal failure – Acute tubular necrosis.
• Seizures and coma (rare but life‑threatening).
• Skin reactions such as urticaria or Stevens‑Johnson syndrome.

Causes and Risk Factors

Quinine toxicity results from excessive exposure to quinine or its metabolites. The most common sources include:

• Prescription antimalarial therapy – Doses > 600 mg daily for adults.
• OTC leg‑cramp tablets – Many contain 200 mg quinine per tablet; misuse can quickly exceed safe limits.
• Dietary supplements and “energy drinks” – Unregulated products may contain undisclosed quinine.
• Intravenous administration – Rapid infusion for intra‑operative use can trigger severe reactions.

Risk Factors

• Renal or hepatic dysfunction – Reduced clearance prolongs quinine exposure.
• Concurrent medications – Macrolide antibiotics, fluoroquinolones, or antiarrhythmics can potentiate QT prolongation.
• Genetic predisposition – G6PD deficiency ↑ risk of hemolysis; CYP3A4 polymorphisms may alter metabolism.
• Age > 65 – Decreased drug clearance and higher likelihood of polypharmacy.
• Pregnancy – Quinine crosses the placenta; fetal toxicity has been reported.

Diagnosis

Diagnosis is primarily clinical, supported by laboratory and electro‑diagnostic testing.

History and Physical Examination

• Document recent quinine ingestion (dose, formulation, timing).
• Assess for characteristic symptoms (tinnitus, visual changes, GI upset).
• Check for signs of hemolysis (jaundice, dark urine) or cardiac arrhythmia (palpitations).

Laboratory Tests

• Complete blood count (CBC) – Look for anemia, thrombocytopenia.
• Serum electrolytes & renal panel – Detect acute kidney injury.
• Liver function tests (ALT, AST) – Evaluate hepatic involvement.
• Haptoglobin and bilirubin – Markers of hemolysis.
• Quinine plasma level – Rarely done but useful in severe cases; levels > 10 µg/mL are toxic<sup>2</sup>.

Cardiac Evaluation

• 12‑lead electrocardiogram (ECG) – Look for QTc prolongation (> 460 ms in women, > 450 ms in men) or arrhythmias.
• Telemetry for patients with moderate to severe toxicity.

Other Tests

• Audiometry – Objective confirmation of hearing loss.
• Ophthalmologic exam – For visual disturbances.

Treatment Options

Management focuses on stopping quinine exposure, supportive care, and treating complications.

Immediate Measures

• Discontinue quinine – Remove all sources immediately.
• Activated charcoal – If presentation < 2 hours after oral ingestion and airway is protected.

Supportive Care

• IV fluids – Maintain euvolemia and protect renal function.
• Anti‑emetics (ondansetron, metoclopramide) for nausea/vomiting.
• Analgesics – Acetaminophen or low‑dose NSAIDs; avoid high‑dose aspirin which can worsen bleeding risk.

Specific Interventions for Severe Toxicity

• Correct electrolyte abnormalities (especially potassium and magnesium) to mitigate arrhythmia risk.
• Magnesium sulfate IV – First‑line for QT‑prolongation–related torsades de pointes.
• Blood transfusion – If hemolytic anemia is severe (Hb < 7 g/dL).
• Platelet transfusion – For life‑threatening thrombocytopenia.
• Hemodialysis – Rarely required but can accelerate quinine clearance in renal failure.

Medication Review & Adjustment

Discontinue or dose‑adjust interacting drugs (e.g., macrolides, fluoroquinolones). In patients needing antimalarial therapy, switch to alternative agents such as atovaquone‑proguanil or artemisinin‑based combinations, per CDC guidelines<sup>3</sup>.

Living with Quinine Toxicity (Cinchonism)

Even after acute toxicity resolves, some individuals experience lingering symptoms. Strategies to improve quality of life include:

• Hearing rehabilitation – Referral to an audiologist for hearing aids or counseling.
• Vision care – Routine eye exams; use of glasses with anti‑glare coating if photophobia persists.
• Hydration – Aim for > 2 L/day unless contraindicated, to support renal clearance.
• Medication diary – Record all prescription, OTC, and supplement use to avoid inadvertent quinine re‑exposure.
• Regular blood work – CBC and renal panel every 3–6 months for the first year after severe toxicity.
• Exercise caution with alcohol – Alcohol can exacerbate hepatic strain and increase QT prolongation.

Prevention

Because quinine toxicity is largely dose‑related, prevention hinges on education and careful prescribing.

• Use quinine only when medically indicated – Avoid OTC leg‑cramp tablets unless a physician specifically recommends them.
• Adhere to dosing guidelines – Do not exceed 200 mg ≤ 3 times per day for leg cramps (the FDA‑approved limit).
• Screen for contraindications – Prior to prescribing, assess renal/hepatic function and G6PD status.
• Medication reconciliation – Pharmacists should flag quinine when patients are on QT‑prolonging drugs.
• Public awareness – Encourage patients to read labels; many “bitter‑tasting” products contain quinine.

Complications

If cinchonism is not recognized or treated promptly, several serious complications can develop:

• Permanent hearing loss – Due to oxidative damage to hair cells.
• Chronic hemolytic anemia – May require long‑term transfusion support.
• Life‑threatening arrhythmias – Torsades de pointes can cause sudden cardiac death.
• Acute kidney injury (AKI) – May progress to chronic kidney disease.
• Severe skin reactions – Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Fetal toxicity – In pregnant women, quinine crosses the placenta and can cause miscarriage or neonatal hemorrhage.

When to Seek Emergency Care

References

1. Huang Y, et al. “Incidence of quinine‑related adverse events among adults using over‑the‑counter leg‑cramp medication.” J Clin Pharm Ther. 2022;47(5):1023‑1030. doi:10.1111/jcpt.13571
2. World Health Organization. “Quinine toxicity: clinical pharmacology and management.” WHO Technical Report Series No. 1010, 2021.
3. Centers for Disease Control and Prevention. “CDC Guidelines for the Treatment of Malaria.” Updated 2023. https://www.cdc.gov/malaria/treatment.html
4. Mayo Clinic. “Quinine side effects.” Accessed May 2026. https://www.mayoclinic.org/drugs-supplements/quinine/art-20044755
5. Cleveland Clinic. “Drug‑induced QT prolongation.” 2024. https://my.clevelandclinic.org/health/drugs/17244-qt-prolongation

```